Dutch biotech company, Crucell N.V and technology partner DSM Biologics have signed a PER.C6 research licence agreement with AbGenomics Corporation based in Taiwan.
Dutch biotech company, Crucell N.V and technology partner DSM Biologics have signed a PER.C6 research licence agreement with AbGenomics Corporation based in Taiwan. AbGenomics Corporations aims to use the PER.C6 cell line for its R&D and early clinical studies of monoclonal antibodies. "The unique characteristics of the PER.C6 technology as a human cell line combined with the short timeline involved in producing clinical material along with the technology's robustness undoubtedly makes our choice for PER.C6 highly imperative," stated Shih-Yao Lin, president of AbGenomics Corporation. The company will make license payments and annual maintenance fees in exchange for certain rights, under the terms of the agreement.
